Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Genome Replication and Regulation of Viral Gene Expression

The Human Cytomegalovirus Gene Products Essential for Late Viral Gene Expression Assemble into Prereplication Complexes before Viral DNA Replication

Hiroki Isomura, Mark F. Stinski, Takayuki Murata, Yoriko Yamashita, Teru Kanda, Shinya Toyokuni, Tatsuya Tsurumi
Hiroki Isomura
1Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hisomura@aichi-cc.jp
Mark F. Stinski
3Department of Microbiology, Carver College of Medicine, University of Iowa, 51 Newton Road, Iowa City, Iowa 52242
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takayuki Murata
1Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoriko Yamashita
2Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teru Kanda
1Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinya Toyokuni
2Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatsuya Tsurumi
1Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.00384-11
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
    • Open in new tab
    • Download powerpoint
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Structure of recombinant HCMV BAC DNAs. (a) Diagram of recombinant BAC DNAs of wt, RdlUL79+F, RdlUL87+F, and RdlUL95+F viruses. When the recombinant HCMV BAC DNA with mutation of the ORF was constructed, the FRT sequence was inserted into the middle of the ORF, and then the Kanr gene was excised by FLP-mediated recombination, leaving only 34 bp of the FRT sequence. (b) Diagram of recombinant BAC DNAs with an epitope fused to the UL95 and UL87 ORFs. When an HA epitope fused to the UL95 ORF was inserted, reverse selection was performed as described in Materials and Methods to remove the drug resistance cassette. To construct BACUL95N neo+St or BACUL95C neo+St, a marker cassette containing the RpsL gene, conferring increased sensitivity to streptomycin, and the neomycin resistance marker, providing kanamycin resistance, was inserted into the N or C terminus of the UL95 ORF, respectively. Intermediate BAC clones were isolated based on resistance to kanamycin. In a second round of homologous recombination, the entire marker cassette was replaced with the sequence containing an HA epitope by counterselection using an oligonucleotide, as described in Materials and Methods. To construct a recombinant BAC with a myc epitope fused to the C terminus of the UL87 ORF, the reverse selection was repeated after construction of BACHAUL95 or BACUL95HA as described in Materials and Methods. To construct a recombinant BAC with a Flag epitope fused to the N terminus of the UL79 ORF, the reverse selection was repeated after construction of BACHAUL95UL87myc or BACUL95HAUL87myc as described in Materials and Methods. (c to e) Growth curves of parental HCMV, RUL95HAUL87myc, RHAUL95UL87myc, RUL95HAUL87mycflagUL79, and RHAUL95UL87mycflagUL79 at an MOI of 3 (c and d) or 0.01 (e). Virus titers were determined by TCID50 assay as described in Materials and Methods.

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    UL79, -87, and -95 are required for viral growth. HFF cells in the presence or absence of the complementary proteins were infected at an MOI of 3. Virus titers were determined by TCID50 assay as described in Materials and Methods. (a) Parental virus; (b) RdlUL79; (c) RdlUL87; (d) RdlUL95.

  • Fig. 3.
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    UL79, -87, and -95 are not required for viral DNA replication. HFF cells in the presence or absence of the complementary protein were infected at an MOI of 3 (a to c) or 0.01 (d to f). Viral DNA was quantified by real-time PCR with gB primers and probe as described in Materials and Methods. Real-time PCR with 18S primers and probe were also performed to serve as an internal control. Data are averages for three independent experiments. (a and d) RdlUL79; (b and e) RdlUL87; (c and f) RdlUL95.

  • Fig. 4.
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    MIE RNA levels are similar in HFF cells at a low MOI but not in HFF cells preexpressing UL79 and UL87. A real-time RT-PCR assay to detect MIE transcripts was performed after infection with the recombinant viruses at a low MOI in HFF cells in the presence or absence of the complementary viral proteins. Total RNA was harvested 1, 2, and 3 days after infection with RdlUL79 (a), RdlUL87 (b), or RdlUL95 (c) at an MOI of 0.01 and was assayed by MIE-specific primers and probe as described in Materials and Methods. The assay was performed in triplicate, and standard errors of the means were determined. HCMV RNAs were normalized to G6PD RNA. Preexpression of UL79 and UL87, but not that of UL95, affected MIE RNA levels at a low MOI.

  • Fig. 5.
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Northern blot analyses of late gene transcription after infection with recombinant viruses. HFF cells in the presence or absence of the complementary protein were infected with the mutant recombinant viruses at an MOI of 3. Cytoplasmic RNA was harvested at 1, 2, and 3 dpi in the presence or absence of PAA as described in Materials and Methods. Northern blots are shown for IE1 (left), UL75 (gH) (middle), and UL99 (pp28) (right). 28S and 18S rRNAs served as controls for equal amounts of RNA loading. Lanes in panel a: 1, 3, and 5, HFF cells; 2, 4, and 6, HFF cells expressing the UL79 fusion protein; 1 and 2, 1 dpi; 3 and 4, 2 dpi; 5 and 6, 3 dpi. Lanes in panels b and c: 1, 3, 5, and 7, HFF cells; 2, 4, 6, and 8, HFF cells expressing the UL87 (b) or UL95 (c) fusion protein; 1 and 2, 1 dpi; 3 and 4, 2 dpi; 5 and 6, 3 dpi (b) or 2 dpi in the presence of PAA (c); 7 and 8, 2 dpi in the presence of PAA (b) or 3 dpi (c). (a) RdlUL79-infected cells; (b) RdlUL87-infected cells; (c) RdlUL95-infected cells.

  • Fig. 6.
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    RNase protection assay for UL44 transcripts after infection with recombinant viruses. Cytoplasmic RNAs were harvested 1, 2, and 3 days after infection with RdlUL79 (a), RdlUL87 (b), or RdlUL95 (c) at an MOI of 3. Twenty micrograms of RNA was hybridized to the 32P-labeled antisense UL44 promoter probe at 37°C overnight before digestion with RNase T1. The antisense UL44 probe contains a sequence upstream of the transcription start site in all UL44 transcripts. The protected RNA fragments were subjected to electrophoresis in denaturing 6% polyacrylamide gels. Lanes in panel a: 1, probe lacking RNase T1; 2, 4, and 6, HFF cells; 3, 5, and 7, HFF cells expressing the UL79 fusion protein; 2 and 3, 1 dpi; 4 and 5, 2 dpi; 6 and 7, 3 dpi. Arrow 1, 2, or 3 indicates the transcript initiating at start site 1, 2, or 3, respectively. Lanes in panels b and c: 1, 3, 5, 7, and 9, HFF cells; 2, 4, 6, 8, and 10, HFF cells expressing the UL87 (b) or UL95 (c) fusion protein; 1 and 2, 1 dpi; 3 and 4, 2 dpi; 5 and 6, 3 dpi (b) or 2 dpi in the presence of PAA (c); 7 and 8, 2 dpi in the presence of PAA (c) or 3 dpi (b).

  • Fig. 7.
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    UL95-HA, UL87-myc, and Flag-UL79 fusion proteins are expressed at early times after infection. Viral DNA synthesis was inhibited with PAA or GCV. Western blot analysis was performed using an antibody against immediate-early proteins pIE86 and pIE72 (UL122 and -123), UL44, the HA, myc, or Flag epitope, or GAPDH at the indicated times after infection with RUL95HAUL87myc or RUL95HAUL97mycflagUL79 in the presence or absence of PAA or GCV as described in Materials and Methods. GAPDH served as a loading control. (a) Anti-HA antibody. (b) Anti-myc antibody. (c) Anti-Flag antibody. (d) Anti-IE72/IE86, anti-UL44, anti-p28, and anti-GAPDH antibodies.

  • Fig. 8.
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Localization of UL95-HA, UL87-myc, and Flag-UL79 fusion proteins, UL44 protein, and viral DNA after infection with recombinant viruses. The cells infected with RUL95HAUL87myc (a to e) or RUL95HAUL87mycflagUL79 (f to h) were harvested at 1 dpi (a and f), 2 dpi (b, d, e, and g), or 3 dpi (c and h). Cells were fixed and treated with antibody for microscopy or for FISH analysis as described in Materials and Methods. (a to c) Colocalization of UL95-HA protein with UL87-myc protein. (d) Colocalization of UL95-HA protein with UL44 protein. (e) Colocalization of viral DNA with UL44 protein. (f to h) Colocalization of Flag-UL79 protein with UL44 protein.

  • Fig. 9.
    • Open in new tab
    • Download powerpoint
    Fig. 9.

    Localization of UL95-HA, UL87-myc, or Flag-UL79 fusion protein after infection with recombinant viruses in the presence of PAA or GCV. Cells infected with RUL95HAUL87myc (a to f and i) or RUL95HAUL87mycflagUL79 (g and h) in the presence of PAA (a, c, e, g, and i) or GCV (b, d, f, and h) were treated at 2 dpi as described in Materials and Methods. (a and b) Colocalization of HCMV DNA and UL44 protein. (c and d) Colocalization of UL95-HA and UL44 proteins. (e and f) Colocalization of UL87-myc and UL44 proteins. (g and h) Colocalization of UL79-Flag and UL44 proteins. (i) Localization of UL87-myc and UL57 proteins.

Tables

  • Figures
  • Table 1.

    PCR primers and oligonucleotides for construction of plasmids and HCMV BAC DNAs for this study

    Primer or oligonucleotideSequence (5′–3′)
    XhoIUL79ORFFCCGCTCGAGATGATGGCCCGCGACGAAGAGAACCC
    HindIIIUL79ORFRCCCAAGCTTTCACGTCGTTAGCCAGCGTCGGCATAT
    XhoIUL95ORFFCCGCTCGAGATGATGGCGGCGGCGGTGGTGCGAGCGGAG
    HindIIIUL95ORFRCCCAAGCTTTTAGATTCAACGTGATGAGACCCGCGTCGTTCAGC
    XhoIUL87ORFFCCGCTCGAGATGGCCGGCGCTGCGCCGCGCCGCCTCGGCTGCGAC
    UL87(815)HindIIIRCAACGCCCAGCCAAAGCTTTTGCAGCTCCAGC
    UL87(815)HindIIIFGCTGGAGCTGCAAAAGCTTTGGCTGGGCGTTG
    HindIIIUL87ORFRCCCAAGCTTTTCGTGATGCAAACCGCGCTCGCGGCGACGTG
    BACdlUL79FRTFKanFGCGGCCGTGTTCGATGAAACGCGCGCCGCCCGTCTCAGCCAGCGCCTGTGTCACCCGCGCTTGAGCGGCGGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAACTCAGCAAAAGTTCGATTTATTCAAC
    BACdlUL79FRTRKanRTTGCGCGCCAGGTCTTCGGGGAAAACGACCGGCAGGCCGGTGTGGCGCTGCACAAAGCGCGTCAGCAGTCGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCTAATGCTCTGCCAGTGTTACAACCA
    BACdlUL87FRTFKanFGTCACTGCCGCGCGACCCGGCCGCAGATCGCGTTCGACGTTACGTATGCATTATCTCGCGGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAACTCAGCAAAAGTTCGATTTATTCAAC
    BACdlUL87FRTRKanRGTCTCCGACCGCCGTTGACAGTGTTTACGCCATCTCTCCCCGTACCGAGCGTACATGAGAGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCTAATGCTCTGCCAGTGTTACAACCA
    BACdlUL95FRTFKanFACGACGCCGCCACGCCGTCTTTTCTACGTCGACACGACGTGCTGGAGCGTTTCGCGGCCGGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAACTCAGCAAAAGTTCGATTTATTCAAC
    BACdlUL95FRTRKanRCACGGTCAGCATTGCGTAACGCATAATCACGCACACAAAGCGACGGCAAAGGCTCAGCCGGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCTAATGCTCTGCCAGTGTTACAACCA
    BACUL95Nneo+StFCTTCTGCAGCTCCGCGTAGCGCTCCTGGATCTTGGCGGCCGAGTCTCCGCGCAACGGCCTGGTGATGATGGCGGGATC
    BACUL95Nneo+StRTTTTCCTCTCCTCTCGCCGCTGCCGCCTAACCTCCGCTCGCACCACCGCCGCCGCTCAGAAGAACTCGTCAAGAAGG
    BACUL95Cneo+StFCGGAAAGTTGCTGGACGCCCTCTCGCTGAACGACGCGGGTCTCATCACGTTGAATGGCCTGGTGATGATGGCGGGATC
    BACUL95Cneo+StRTCAAGGTCGACGCGCATCACGTCCTTTAAGAGCTGTTTGTTGACCGACGTCATAGTCAGAAGAACTCGTCAAGAAGG
    BAColigoHAUL95TTGCGCTTCTGCAGCTCCGCGTAGCGCTCCTGGATCTTGGCGGCCGAGTCTCCGCGCAACATGTACCCATACGATGTTCCAGATTACGCTGCGGCGGCGGTGGTGCGAGCGGAGGTTAGGCGGCAGCGGCGAGAGGAGAGGAAAAAGATG
    BACUL95ColigoCCACGTCGGAAAGTTGCTGGACGCCCTCTCGCTGAACGACGCGGGTCTCATCACGTTGAATTACCCATACGATGTTCCAGATTACGCTCTATGACGTCGGTCAACAAACAGCTCTTAAAGGACGTGATGCGCGTCGACCTTGAGCGACA
    BACUL87Cneo+StFCAGCGTTGACGGCAGTTCTGAACCCACGTCGCCGCGAGCGCGGTTTGCATCACGAGGCCTGGTGATGATGGCGGGATC
    BACUL87Cneo+StRGTCGGACGCTCCTCCGGACGAAACGCCGCGGCGGCAGCGGCCGCGGCTTCCATCATCAGAAGAACTCGTCAAGAAGG
    BACUL87oligoTCCGTCAGCGTTGACGGCAGTTCTGAACCCACGTCGCCGCGAGCGCGGTTTGCATCACGAGAACAGAAACTGATCTCTGAAGAAGACCTGTGATGGAAGCCGCGGCCGCTGCCGCCGCGGCGTTTCGTCCGGAGGAGCGTCCGACGCCGG
    BACUL79NFneoCACAGCCTGCGGCTGCTGCTCGTCCATCGTCATTGTCGTCACCGTCGCTACCCGCTCACCGAGCGAACGGGCCTGGTGATGATGGCGGGATC
    BACUL79NRneoGATTGGCGCAAGTAAAGGAGAATTTGCCTGTGCGGACCCGCGGGACGGCGGGGTTCTCTTCGTCGCGGGCTCAGAAGAACTCGTCAAGAAGG
    BAColigoflagUL79GCGGCTGCTGCTCGTCCATCGTCATTGTCGTCACCGTCGCTACCCGCTCACCGAGCGAACGATGGACTACAAAGACGATGACGACAAGGCCCGCGACGAAGAGAACCCCGCCGTCCCGCGGGTCCGCACaGGCAAATTCTCCTTTACTTG
    UL79detectFCGCCAGGCCTTCCCGGGGCTGG
    UL79detectRCCGTAGAGCGTGCCTAGGGAGAAGAGG
    UL87BACdetectFCGATCCGTAAGCCGCGGTTACGG
    UL87BACdetectRCGTAAAGTCAAATGGCGGCGTGGCG
    UL95BACdetectFGGGAAAAGAACGGCGGTGGGTCTCG
    UL95BACdetectRGCTGGAGAGTGACAGCTCCACGTGAGC
    UL95NdetectFAGTTCGGGGTGCATCATCT
    UL95NdetectRACGACACCACTAGGGACGAC
    UL95CdetectFAAGTTGCTGGACGCCCTCTC
    UL95CdetectRACACGCATCACCGTCAAAG
    UL87CdetectFCCCATTGTGTGTGTCCTCAT
    UL87CdetectRCCGTACCGTCGTCCATTAAC
    UL79NdetectNGGTCGTAACGGGCGAGAAAGCCG
    UL79NdetectRCTGTCCGCGCGACATCTTCTCGC
PreviousNext
Back to top
Download PDF
Citation Tools
The Human Cytomegalovirus Gene Products Essential for Late Viral Gene Expression Assemble into Prereplication Complexes before Viral DNA Replication
Hiroki Isomura, Mark F. Stinski, Takayuki Murata, Yoriko Yamashita, Teru Kanda, Shinya Toyokuni, Tatsuya Tsurumi
Journal of Virology Jun 2011, 85 (13) 6629-6644; DOI: 10.1128/JVI.00384-11

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Human Cytomegalovirus Gene Products Essential for Late Viral Gene Expression Assemble into Prereplication Complexes before Viral DNA Replication
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Human Cytomegalovirus Gene Products Essential for Late Viral Gene Expression Assemble into Prereplication Complexes before Viral DNA Replication
Hiroki Isomura, Mark F. Stinski, Takayuki Murata, Yoriko Yamashita, Teru Kanda, Shinya Toyokuni, Tatsuya Tsurumi
Journal of Virology Jun 2011, 85 (13) 6629-6644; DOI: 10.1128/JVI.00384-11
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514